CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing).
Read more at globenewswire.comTrevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
